Stock analysts at StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.
Separately, Dawson James initiated coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday, February 28th. They issued a “buy” rating and a $3.00 target price for the company.
Get Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Trading Up 7.2 %
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. Equities research analysts predict that Tonix Pharmaceuticals will post -3.18 EPS for the current fiscal year.
Institutional Investors Weigh In On Tonix Pharmaceuticals
A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC raised its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 160.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,770,000 shares of the company’s stock after purchasing an additional 2,320,000 shares during the period. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 82.26% of the company’s stock.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Further Reading
- Five stocks we like better than Tonix Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 4/29 – 5/3
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- 5 discounted opportunities for dividend growth investors
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.